79MO PACIFIC-R: Real-world characteristics of unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy

Background: The PACIFIC regimen (up to 12 months of durvalumab treatment in pts with unresectable stage III non-small cell lung cancer [NSCLC] who did not progress after platinum-based concurrent chemoradiotherapy [cCRT]) is now standard of care. Insights into durvalumab use outside the clinical trial setting are needed. Methods: PACIFIC-R (NCT03798535) is a large international, observational study of pts with unresectable Stage III NSCLC who...